A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
- 5 August 2009
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 65 (4) , 649-660
Abstract
Purpose Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) bear a grave prognosis. There are unmet needs for the development of novel agents for this incurable disease. Angiogenesis is an important biological process in SCCHN. We, therefore, evaluated the activity and safety of sunitinib, an oral tyrosine kinase inhibitor that targets multiple receptors, in patients with RM-SCCHN. Patients and methods Seventeen patients were treated with sunitinib 50 mg per day administrated in 4-week cycles followed by a rest period of 2 weeks. Sunitinib and SU012662 plasma levels were determined based on a validated liquid chromatography-tandem mass spectrometry method and pharmacokinetic data were fitted in a non-compartmental analysis. Results Totally, 28 6-week cycles of treatment with sunitinib were administered (median, 2 cycles). Only three patients demonstrated stabilization of the disease; therefore, the study had to be terminated prematurely due to futility. Grade 3 toxicities, apart from fatigue, were infrequent. Other frequently reported side effects were skin discoloration, neutropenia, and thrombocytopenia. Ten various bleeding complications were reported in seven patients. Mean maximum concentrations (C max) were reached during the first day of treatment for sunitinib at 38.98 (±22.66) ng/ml and for SU012662 at 11.12 (±24.57) ng/ml. Our results showed that SU012662 has a longer half-life and a larger volume of distribution than the parent drug sunitinib. None of the biological markers tested was of any prognostic value. Conclusions According to our findings, sunitinib monotherapy was not proven active in RM-SCCHN, and no further development of the drug in this indication is warranted.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic Significance of Tumor Hypoxia Inducible Factor–1α Expression for Outcome After Radiotherapy in Oropharyngeal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Recurrent head and neck cancer: current treatment and future prospectsExpert Review of Anticancer Therapy, 2008
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2006
- Angiogenesis as a therapeutic targetNature, 2005
- Raf: A Strategic Target for Therapeutic Development Against CancerJournal of Clinical Oncology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005